Publikationen 2002
Originalarbeiten
- Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100(9):3101-7.
- Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A; German Hodgkin's Lymphoma Study Group (GHSG). A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann Hematol. 2002; 81(8):424-9.
- Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002; 20(1):221-30.
- Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002; 13(10):1628-35.
- Krupicka J, Marková J, Pohlreich D, Kozák T, Línková H, Diehl V; German Hodgkin's Lymphoma Study Group. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group. Leuk Lymphoma. 2002 Dec;43(12):2325-9.
- Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002; 20(2):476-84. [ENDAUSWERTUNG HD5]
- Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 2002; 8(6):1779-86.
- Weihrauch MR, Re D, Bischoff S, Scheidhauer K, Dietlein M, Ansen S, Franklin J, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematology 2002; 81: 20-25.
- Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71. [ENDAUSWERTUNG HD-R1]
Übersichtsarbeiten
- Ansén S, Sieber M, Wingbermühle K, Josting A, Diehl V. [Current therapeutic strategies in Hodgkin lymphoma].Internist (Berl). 2002; 43(12):1544-50.
- Diehl V. [Interview with Professor Dr. Volker Diehl, Cologne. Hodgkin disease: on the path to causal therapy?].MMW Fortschr Med. 2002; 31:144(5):8.
- Franklin J, Diehl V. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol. 2002; 13 Suppl 1:98-101
- Glossmann JP, Josting A, Diehl V. New treatments for Hodgkin's disease. Curr Treat Options Oncol. 2002; 3(4):283-90.
- Josting A, Raemakers JM, Diehl V, Engert A. New concepts for relapsed Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 1:117-21.
- Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 1:112-6.
- Re D, Zander T, Diehl V, Wolf J. Genetic instability in Hodgkin's lymphoma. Ann Oncol. 2002; 13 Suppl 1:19-22.
- Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 1: 57-66.
- Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol. 2002; 13 Suppl 4:147-52.